首页> 美国卫生研究院文献>Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders >US-Approved Intra-Articular Hyaluronic Acid Injections are Safe and Effective in Patients with Knee Osteoarthritis: Systematic Review and Meta-Analysis of Randomized Saline-Controlled Trials
【2h】

US-Approved Intra-Articular Hyaluronic Acid Injections are Safe and Effective in Patients with Knee Osteoarthritis: Systematic Review and Meta-Analysis of Randomized Saline-Controlled Trials

机译:美国批准的关节内透明质酸注射液对膝骨关节炎患者是安全有效的:随机盐水对照试验的系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We conducted a systematic review and meta-analysis of randomized saline-controlled trials to determine the safety and efficacy of US-approved intra-articular hyaluronic acid (IAHA) injections for symptomatic knee osteoarthritis. A total of 29 studies representing 4,866 unique subjects (IAHA: 2,673, saline: 2,193) were included. IAHA injection resulted in very large treatment effects between 4 and 26 weeks for knee pain and function compared to pre-injection values, with standardized mean difference (SMD) values ranging from 1.07–1.37 (all P < 0.001). Compared to saline controls, SMDs with IAHA ranged from 0.38–0.43 for knee pain and 0.32–0.34 for knee function (all P < 0.001). There were no statistically significant differences between IAHA and saline controls for any safety outcome, including serious adverse events (SAEs) (P = 0.12), treatment-related SAEs (P = 1.0), study withdrawal (P = 1.0), and AE-related study withdrawal (P = 0.46). We conclude that intra-articular injection of US-approved HA products is safe and efficacious in patients with symptomatic knee osteoarthritis.
机译:我们对随机对照试验进行了系统的回顾和荟萃分析,以确定美国批准的关节内透明质酸(IAHA)注射液治疗症状性膝骨关节炎的安全性和有效性。总共包括29个研究,代表4,866个独特的受试者(IAHA:2,673,盐水:2,193)。与注射前的值相比,IAHA注射可在4至26周内对膝部疼痛和功能产生非常大的治疗效果,标准均值(SMD)值在1.07-1.37之间(所有P <0.001)。与生理盐水对照组相比,IAHA的SMD膝关节疼痛范围为0.38-0.43,膝关节功能范围为0.32-0.34(所有P <0.001)。 IAHA与生理盐水对照之间的任何安全性结局,包括严重不良事件(SAE)(P = 0.12),与治疗相关的SAE(P = 1.0),研究退出(P = 1.0)和AE-相关研究退出(P = 0.46)。我们得出的结论是,关节内注射经过美国批准的HA产品在有症状的膝骨关节炎患者中是安全有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号